Vimal Mehta Bio Xcel Therapeutics, Inc. (BTAI) insider trading activity

BTAI Quotes by TradingView

Vimal Mehta is CEO and President of BioXcel Therapeutics, Inc.. Currently has a direct ownership of 59,605 shares of BTAI, which is worth approximately $24,438. The most recent transaction as insider was on Dec 16, 2024, when has been sold 3,117 shares (Common Stock) at a price of $0.36 per share, resulting in proceeds of $1,122. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 59.6K
15.37% 3M change
84.98% 12M change
Total Value Held $24,438

Vimal Mehta Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 16 2024
SELL
Open market or private sale
$1,122 $0.36 p/Share
3,117 Reduced 4.97%
59,605 Common Stock
Dec 15 2024
BUY
Exercise of conversion of derivative security
-
3,500 Added 5.35%
61,903 Common Stock
Dec 14 2024
BUY
Exercise of conversion of derivative security
-
2,610 Added 4.28%
58,403 Common Stock
Sep 16 2024
SELL
Open market or private sale
$1,367 $0.69 p/Share
1,982 Reduced 3.69%
51,666 Common Stock
Sep 15 2024
BUY
Exercise of conversion of derivative security
-
3,500 Added 6.12%
53,648 Common Stock
Sep 14 2024
BUY
Exercise of conversion of derivative security
-
2,609 Added 4.95%
50,148 Common Stock
Jun 17 2024
SELL
Open market or private sale
$2,731 $1.28 p/Share
2,134 Reduced 4.3%
47,539 Common Stock
Jun 15 2024
BUY
Exercise of conversion of derivative security
-
3,500 Added 6.58%
49,673 Common Stock
Jun 14 2024
BUY
Exercise of conversion of derivative security
-
2,609 Added 5.35%
46,173 Common Stock
Apr 04 2024
SELL
Open market or private sale
$13,802 $2.62 p/Share
5,268 Reduced 10.79%
43,564 Common Stock
Mar 15 2024
BUY
Exercise of conversion of derivative security
-
14,000 Added 22.28%
48,832 Common Stock
Mar 14 2024
BUY
Exercise of conversion of derivative security
-
2,610 Added 6.97%
34,832 Common Stock
Dec 14 2023
BUY
Exercise of conversion of derivative security
-
2,609 Added 7.49%
32,222 Common Stock
Sep 14 2023
BUY
Exercise of conversion of derivative security
-
2,610 Added 8.1%
29,613 Common Stock
Jun 16 2023
SELL
Open market or private sale
$627,900 $20.93 p/Share
30,000 Reduced 42.92%
39,903 Common Stock
Jun 16 2023
BUY
Exercise of conversion of derivative security
$12,300 $0.41 p/Share
30,000 Added 30.03%
69,903 Common Stock
Jun 15 2023
SELL
Open market or private sale
$649,800 $21.66 p/Share
30,000 Reduced 42.92%
39,903 Common Stock
Jun 15 2023
BUY
Exercise of conversion of derivative security
$12,300 $0.41 p/Share
30,000 Added 30.03%
69,903 Common Stock
Jun 14 2023
BUY
Exercise of conversion of derivative security
-
2,609 Added 6.14%
39,903 Common Stock
May 22 2023
SELL
Open market or private sale
$167,635 $25.79 p/Share
6,500 Reduced 14.84%
37,294 Common Stock
May 14 2023
BUY
Exercise of conversion of derivative security
-
15,000 Added 32.68%
30,894 Common Stock
Mar 21 2023
SELL
Open market or private sale
$597,900 $19.93 p/Share
30,000 Reduced 65.37%
15,894 Common Stock
Mar 21 2023
BUY
Exercise of conversion of derivative security
$12,300 $0.41 p/Share
30,000 Added 39.53%
45,894 Common Stock
Mar 20 2023
SELL
Open market or private sale
$639,630 $18.54 p/Share
34,500 Reduced 68.46%
15,894 Common Stock
Mar 20 2023
BUY
Exercise of conversion of derivative security
$12,300 $0.41 p/Share
30,000 Added 37.32%
50,394 Common Stock
VM

Vimal Mehta

CEO and President
New Haven, CT

Track Institutional and Insider Activities on BTAI

Follow BioXcel Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BTAI shares.

Notify only if

Insider Trading

Get notified when an Bio Xcel Therapeutics, Inc. insider buys or sells BTAI shares.

Notify only if

News

Receive news related to BioXcel Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on BTAI